Go to
JCI Insight
Citations to this article
S Gupta, … , J Kim, S Gollapudi
Published April 1, 1991
Citation Information: J Clin Invest. 1991;87(4):1467-1469. https://doi.org/10.1172/JCI115154.
Citation Information: J Clin Invest. 1991;87(4):1467-1469. https://doi.org/10.1172/JCI115154.
Abstract
Itraconazole is a recently developed triazole antifungal agent that inhibits cell membrane sterol biosynthesis. Itraconazole, in a dose-dependent manner, enhanced intracellular accumulation of daunorubicin and reversed the drug resistance in murine leukemia P388/ADR cells. In addition, itraconazole corrected the altered plasma membrane potentials of P388/ADR cells. The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections. Therefore, itraconazole is a potential candidate for in vivo use to reverse multidrug resistance in cancer with added benefit of its antifungal property.
Authors
S Gupta, J Kim, S Gollapudi
Total citations by year
Citation information
Citations to this article in year 2014 (1)
| Title and authors | Publication | Year |
|---|---|---|
|
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
RE Kast, G Karpel-Massler, ME Halatsch |
Oncotarget | 2014 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)